




Cancer Research

OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH



June 15, 1993
Volume 53 • Number 12
PP. 2697-2935
ISSN 0008-5472 • CNREA 8

WE FIND PATHS WHERE
OTHERS FAIL TO LOOK

At the Sandoz Cytokine Development Unit (CDU), we are exploring new paths of research and development and studying more options in disease treatment than were ever thought possible. Using the latest technology, the CDU is working to develop these treatments rapidly, with the same high-quality standards we have always upheld.

At the CDU, our commitment to research and development is unsurpassed. Sandoz created the

CDU as an independent unit, fueled by the dedication of specialized personnel. These highly skilled individuals have been brought together for a common goal—to explore new paths of therapy.



INTERACTIONS OF CANCER SUSCEPTIBILITY GENES AND ENVIRONMENTAL CARCINOGENS

Joint Meeting Organized by the
American Association for Cancer Research (AACR)
and the International Agency for Research on Cancer (IARC)

November 9-13, 1993
Lyon, France



CONFERENCE CHAIRPERSONS
Frederick P. Li / Boston, USA
Ruggero Montesano / Lyon, France



PROGRAM COMMITTEE

Kari K. Alitalo / Helsinki, Finland
J. Carl Barrett / Research Triangle Park, USA
Valerie Beral / Oxford, England
Dirk Bootsma / Rotterdam, The Netherlands
Curtis C. Harris / Bethesda, USA
Henry C. Pitot / Madison, USA

Bruce A. J. Ponder / Cambridge, England
Carmen Sapienza / La Jolla, USA
Takashi Sugimura / Tokyo, Japan
Lorenzo Tomatis / Lyon, France
Lee W. Wattenberg / Minneapolis, USA
I. Bernard Weinstein / New York, USA

SCIENTIFIC PROGRAM

Introductory Lectures

Curtis C. Harris / Bethesda, USA
Lorenzo Tomatis / Lyon, France
Lee W. Wattenberg / Minneapolis, USA
Manfred F. Rajewsky / Essen, Germany

Genetic Instability

Kari K. Alitalo / Helsinki, Finland
T. Heidmann / Paris, France
Thea D. Tlsty / Chapel Hill, USA

Experimental Models of Genetic Susceptibility

J. Carl Barrett / Research Triangle Park, USA
Henry C. Pitot / Madison, USA
Bernard M. Mechler / Heidelberg, Germany

DNA Damage and Repair

Dirk Bootsma / Rotterdam, The Netherlands
John M. Essigmann / Cambridge, USA
Mutsuo Sekiguchi / Fukuoka, Japan

Mechanisms of Transgenerational Carcinogenesis

Carmen Sapienza / La Jolla, USA
Ulrike Wintersberger / Vienna, Austria
David Malkin / Toronto, Canada
Christopher J. Kemp / Glasgow, Scotland

Human Cancers

Frederick P. Li / Boston, USA
Valerie Beral / Oxford, England
Bruce A. J. Ponder / Cambridge, England
Neil E. Caporaso / Bethesda, USA
Gilbert M. Lenoir / Lyon, France

Markers of Individual Exposure

Ruggero Montesano / Lyon, France
Peter A. Cerutti / Epalinges, Switzerland

Opportunities for Prevention

I. Bernard Weinstein / New York, USA

*Applicants are encouraged to submit abstracts
for poster presentation.*

Information and Application Forms

American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483
(215) 440-9300 (215) 440-9313 (FAX)

AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Cell Death in Cancer and Development

October 17-21, 1993
Chatham Bars Inn, Chatham (Cape Cod), Massachusetts



CONFERENCE CHAIRPERSON

Alan R. Eastman / Hanover, NH

PROGRAM COMMITTEE

Nathan A. Berger / Cleveland, OH
H. Robert Horvitz / Boston, MA
John T. Isaacs / Baltimore, MD

Stanley J. Korsmeyer / St. Louis, MO
Thomas R. Tritton / Burlington, VT
Andrew H. Wyllie / Edinburgh, Scotland

SCIENTIFIC PROGRAM

Keynote Address

Andrew H. Wyllie / Edinburgh, Scotland

Cell Death and Development

Martin C. Raff / London, England
H. Robert Horvitz / Boston, MA
Lawrence Schwartz / Amherst, MA
Hermann Steller / Cambridge, MA

Cell Death in the Pathogenesis of Cancer

John T. Isaacs / Baltimore, MD
Rolf Schulte-Hermann / Vienna, Austria
David P. Lane / Dundee, Scotland

Suppression of Cell Death

Stanley J. Korsmeyer / St. Louis, MO
Eileen White / Piscataway, NJ
William Sugden / Madison, WI
Ruth Craig / Hanover, NH

Enzymology of Cell Death

John A. Cidlowski / Chapel Hill, NC
Alan R. Eastman / Hanover, NH
Peter J.A. Davies / Houston, TX

Cell Death in the Immune System

Peter H. Kramer / Heidelberg, Germany
Douglas R. Green / LaJolla, CA
Jonathan D. Ashwell / Bethesda, MD
Arnold H. Greenberg / Winnipeg, Manitoba, Canada

Genetic Events Associated with Cell Death

J. John Cohen / Denver, CO
Barbara Osborne / Amherst, MA
Ralph E. Buttyan / New York, NY
Robert Schlegel / Boston, MA

Cell Death in Cancer Chemotherapy

Nathan A. Berger / Cleveland, OH
Yves G. Pommier / Bethesda, MD
Nancy L. Oleinick / Cleveland, OH
Carlos J. Carrera / San Diego, CA

Applicants are encouraged to submit abstracts for poster presentation.

Information and Application Forms

American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483

Application Deadline: June 28, 1993

215-440-9300 215-440-9313 (FAX)

AACR SPECIAL CONFERENCE IN CANCER RESEARCH

Molecular Approaches to Cancer Immunotherapy

November 7-11, 1993
The Grove Park Inn, Asheville, North Carolina

CONFERENCE CHAIRPERSON

Ralph A. Reisfeld / La Jolla, CA



SCIENTIFIC PROGRAM

Keynote Address

Giorgio Trinchieri / Philadelphia, PA

Monoclonal Antibodies for Tumor Therapy

Alan N. Houghton / New York, NY

Albert F. LoBuglio / Birmingham, AL

Ira Pastan / Bethesda, MD

David A. Scheinberg / New York, NY

Genetically Engineered Antibodies

Stephen D. Gillies / Lexington, MA

Jeffrey Schlom / Bethesda, MD

Richard P. Junghans / Boston, MA

Sherie L. Morrison / Los Angeles, CA

Clive Woodhouse / Mountain View, CA

Gene Therapy of Cancer

James J. Mulé / Palo Alto, CA

Drew M. Pardoll / Baltimore, MD

David T. Curiel / Chapel Hill, NC

Patrick Hwu / Bethesda, MD

Elizabeth Jaffee / Baltimore, MD

Cytokines in Tumor Therapy

Steven Gillis / Seattle, WA

Roland Mertelsmann / Freiburg, Germany

Ronald Levy / Stanford, CA

Terry Strom / Boston, MA

Tumor Antigens Recognized by T-Cells

Olivera J. Finn / Pittsburgh, PA

Per A. Peterson / La Jolla, CA

Martin A. Cheever / Seattle, WA

Michael T. Lotze / Pittsburgh, PA

Antibodies as Immunogens

Soldano Ferrone / Valhalla, NY

Dorothee Herlyn / Philadelphia, PA

Kenneth Foon / Lexington, KY

Alan N. Houghton / New York, NY

Future of Cancer Immunotherapy

Isaiah J. Fidler / Houston, TX

Paul M. Sondel / Madison, WI

Irwin D. Bernstein / Seattle, WA

Eugenie S. Kleinerman / Houston, TX

Applicants are encouraged to submit abstracts for poster presentation.

Information and Application Forms

American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483

215-440-9300 215-440-9313 (FAX)

Application Deadline: August 2, 1993



AMERICAN ASSOCIATION FOR CANCER RESEARCH SCIENTIFIC CONFERENCES: 1993-1994

OCTOBER 17-21, 1993

Cell Death and Cancer

Chairperson: Alan R. Eastman, Hanover, NH
Chatham Bars Inn, Chatham (Cape Cod), MA

NOVEMBER 7-11, 1993

***Molecular Approaches to
Cancer Immunotherapy***

Chairperson: Ralph A. Reisfeld, San Diego, CA
Grove Park Inn, Asheville, NC

NOVEMBER 9-13, 1993

***Interactions of Cancer Susceptibility
Genes and Environmental Carcinogens***

Joint Meeting with International Agency for
Research on Cancer (IARC)
Chairpersons: Frederick P. Li, Boston, MA, and
Ruggero Montesano, Lyon, France
IARC, Lyon, France

DECEMBER 5-9, 1993

Cell Signalling and Cancer Treatment

Joint Meeting with British Association for
Cancer Research and European
Organisation for Research and Treatment
of Cancer (PAM Group)
Chairpersons: Garth Powis, Tucson, AZ;
Paul Workman, Glasgow, Scotland
El San Juan Hotel, San Juan, PR

JANUARY 17-22, 1994

***Risk Assessment in Environmental
Carcinogenesis***

Co-Sponsored by the
Environmental Mutagen Society
Chairpersons: Philip C. Hanawalt, Stanford, CA;
James A. Swenberg, Chapel Hill, NC
Whistler Resort and Conference Center, Whistler,
B.C., Canada

JANUARY 31-FEBRUARY 5, 1994

***Molecular Genetics of Progression
and Metastasis***

Chairperson: Lance A. Liotta, Bethesda, MD
Big Sky Resort, Big Sky, MT

FEBRUARY 19-24, 1994

***Cancer: Perturbation in Cell Cycle
Control and Genomic Integrity***

Chairpersons: Thea D. Tlsty, Chapel Hill, NC;
Lawrence A. Loeb, Seattle, WA
Banff Springs Hotel, Banff, Alberta, Canada

MARCH 5-11, 1994

Growth Factors, Development, and Cancer

Joint Meeting with Friedrich-Miescher Institut
Chairpersons: Harold L. Moses, Nashville, TN;
Bernd Groner, Basel, Switzerland
Congress Center, Interlaken, Switzerland

APRIL 10-13, 1994

85th Annual Meeting

Chairperson: Karen S. H. Antman, Boston, MA
Moscone Convention Center, San Francisco, CA

OCTOBER 16-20, 1994


***Transcriptional Regulation in
Differentiation (Tentative Title)***

Chairpersons: Eric N. Olson, Houston, TX; Bruce
M. Spiegelman, Boston, MA
Chatham Bars Inn, Chatham (Cape Cod), MA

AACR members will receive brochures on the
above special conferences as soon as they are
available. Nonmembers should call or write:

American Association for Cancer Research
Public Ledger Building
620 Chestnut Street, Suite 816
Philadelphia, PA 19106-3483
215-440-9300 • 215-440-9313 (FAX)

COVER LEGEND



Henry Mihich, M.D., in a 30-year career, has achieved distinction primarily from his studies on the interaction of drugs with the immune system as they affect cancer cell growth. As a part of these investigations, he demonstrated: that host immune defense is indispensable to the antitumor effects of diverse chemotherapeutic agents against transplantable mouse tumors; that mouse leukemic sublines resistant to certain antitumor agents are more immunogenic and antigenic than the parent cell lines; that certain anticancer agents selectively inhibit preformed immune effector functions; that Adriamycin selectively augments macrophage differentiation, increasing cytotoxic T-lympho-

cyte responses and inhibiting interleukin 1 production; and that the cyclophosphamide metabolite 4-hydroxypoxycyclophosphamide inhibits selectively precursors of T-suppressor cells.

In addition to these fundamental studies, he has brought various drugs to clinical trial, including methylglyoxal bis (guanylhydrazone). His work has been published in 107 papers and reviewed in 23 book chapters and 14 symposium lectures.

As Director of the Grace Cancer Drug Center at Roswell Park Cancer Institute, Buffalo, NY, he has built a strong department focused on medicinal chemistry, preclinical biochemical pharmacology, and experimental therapeutics. He has been cognizant of the need to develop a strong basic background on the fundamental nature of cancer to improve drug treatment and has strengthened collaboration of basic with clinical departments. As Chairman of the Pharmacology Department within the Roswell Park Division of the Graduate School of the State University of Buffalo, he heads a department that currently has 17 predoctoral students and 23 postdoctoral fellows.

He has contributed significantly to the advancement of cancer research and treatment through his membership on policy-making bodies such as the Board of Scientific Counselors of the National Cancer Institute's Division of Cancer Treatment and the National Cancer Advisory Board, and as President of the American Association for Cancer Research (1987-1988). He has also participated in numerous cooperative working groups between the United States and France, Italy, and Japan, and has served on nine study sections and on the editorial boards of 12 peer-reviewed journals.

Edwin A. Mirand